Cabozantinib Granted Breakthrough Therapy Designation for Kidney Cancer
the ONA take:
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma (RCC) after a prior therapy administration.
The FDA designation was based on resulting data from METEOR, a phase 3 trial that compared cabozantinib vs everolimus in patients with advanced renal cell carcinoma. Participants all experienced disease progression after treatment with a VEGF receptor tyrosine kinase inhibitor.
Cabozantinib displayed a significant increase in progression-free survival when compared to everolimus treatment in the first 375 randomly chosen participants, with disease progression or death dropping by approximately 42 percent. RCC treatment has historically been limited to cytokine therapy before the more recent use of targeted therapies.
The Breakthrough Therapy Designation is assigned in cases where a drug demonstrates significant benefit and/or life-saving benefits when compared to traditional therapies.
The benefits of the Breakthrough Therapy Designation may include expedited review of a New Drug Application and the involvement of senior FDA managers in the review process.
Cabozantinib, marketed in capsule form under the trade name Cometriq, is currently FDA-approved for the treatment of metastatic medullary thyroid cancer. Cabozantinib inhibits the activity of tyrosine kinases active in oncogenesis, metastasis, and tumor angiogenesis processes.
The FDA has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|